Gossamer’s serartinib is designed to treat pulmonary arterial hypertension and other indications
Chiesi Group and Gossamer Bio announced a global collaboration and licensing agreement to develop and commercialize serartinib to treat respiratory diseases.
Chiesi will support Gossamer’s ongoing research on serartinib for pulmonary arterial hypertension (PAH) and the development of serartinib in pulmonary hypertension associated with interstitial lung disease (PH-ILD).
PAH is a rare, progressive disease that is estimated to affect up to 50,000 people in the United States and causes high blood pressure in the pulmonary arteries. It is estimated that up to 100,000 patients in the United States are affected by her PH-ILD.
Serartinib is an inhalation inhibitor designed to be delivered via a dry powder inhaler for the potential treatment of pulmonary hypertension.
As part of the agreement, Chiesi will pay Gossamer $160 million in development reimbursement, and the biopharmaceutical company will receive up to $146 million in regulatory milestones and up to $180 million in sales milestones. You can also get qualifications.
Under the terms of the agreement, Gossamer will lead the global development of serartinib in PAH and PH-ILD, and the companies will split development costs, excluding the PROSERA trial.
Both companies will share commercial profits and losses equally and contribute 50% of commercial activity in the U.S., while Gossamer will lead commercialization and sales for PAH and PH-ILD, and Chiesi will lead commercialization and sales for additional indications. leading commercialization in
Additionally, Chiesi will receive exclusive rights to commercialize serartinib outside the United States and will pay Gossamer a royalty in the mid-to-high teens on net sales.
Faheem Hasnain, co-founder, chairman and CEO of Gossamer, commented: “This collaboration allows serartinib to move directly into Phase 3 trials in the indication PH-ILD, a disease for which there is a paucity of available treatments and where serartinib is likely to be effective. ” specifically designed to deal with. ”
Giuseppe Accogli, Chief Executive Officer of Chiesi Group, said: “Serartinib has the potential to be a paradigm-shifting therapy in PAH and PH-ILD, and we… “We’re excited to be able to offer this to our patients.”
